Catalist-listed SIAMH may have gone public before it was ready – MAS review group should figure out why
Can the enablers of public listings be incentivised to ensure that companies do not come to market without a credible growth story?
WHEN news broke earlier this month that the external auditors of the Singapore Institute of Advanced Medicine Holdings (SIAMH) had issued a disclaimer of opinion on its latest financial statements, I imagined that the company’s share price would immediately plummet.
Then, I looked at my trading screen and realised the stock could not plummet because it was already on the floor – and had been for some time.
SIAMH listed on Catalist on Feb 16, following an initial public offering (IPO) at S$0.23 per share. It ended its first trading day at S$0.19. Less than a fortnight later, its shares had crashed below S$0.10.
TRENDING NOW
8 public officers referred to police over property buys near unannounced MRT stations: Chan Chun Sing
DBS tops trades in smaller board lots on debut of revised SGX framework
Grab CEO’s wife Chloe Tong on life with Anthony Tan and finding her purpose
Retrenched PMETs who return on lower pay see median 25% wage cut